ea0037gp.28.05 | Endocrine tumours and neoplasia – NETS | ECE2015
Vitali Eleonora
, Cambiaghi Valeria
, Loiarro Federica
, Zerbi Alessandro
, Colombo Piergiuseppe
, Spada Anna
, Mantovani Giovanna
, Peverelli Erika
, Carnaghi Carlo
, Lania Andrea
Somatostatin receptor type 2 (SST2) is the main pharmacological target of long-acting somatostatin analogues (SSA) widely used in patients with pancreatic neuroendocrine tumours (P-NETs). A subset of patients is resistant to SSA, although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein interactions as determinant in receptor anchoring, expression and signalling. Since SST2 was recently demonstrated to a...